Abbott has finalized its acquisition of Exact Sciences, positioning itself as a leader in the rapidly growing cancer screening and diagnostics market. This move expands Abbott's reach in early cancer detection and personalized treatment, adding key products like Cologuard and Oncotype DX to its portfolio. The acquisition supports Abbott's goal to advance preventative and personalized healthcare, tapping into a $60 billion U.S. cancer diagnostics market. Exact Sciences is now a wholly owned subsidiary, with its shares delisted from Nasdaq as of March 20, 2026.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
